Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan
- Conditions
- Hypertension
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1856
- Registration Number
- NCT01108796
- Locations
- 🇸🇮
Boehringer Ingelheim Investigational Site 160, Tur?ianske Teplice, Slovenia
🇸🇮Boehringer Ingelheim Investigational Site 169, Zeliezovce, Slovenia
🇸🇮Boehringer Ingelheim Investigational Site 95, Nové Mesto nad Váhom, Slovenia
An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 324
- Registration Number
- NCT01103960
- Locations
- 🇨🇳
1235.29.86002 Boehringer Ingelheim Investigational Site, Shanghai, China
🇵🇭1235.29.63018 Boehringer Ingelheim Investigational Site, Metro Manila, Philippines
🇨🇳1235.29.86001 Boehringer Ingelheim Investigational Site, Beijing, China
BI 671800 in Asthmatic Patients on Inhaled Corticosteroids
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 243
- Registration Number
- NCT01103349
- Locations
- 🇳🇿
1268.16.64003 Boehringer Ingelheim Investigational Site, Greenlane East Auckland, New Zealand
🇩🇪1268.16.49004 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇰🇷1268.16.82009 Boehringer Ingelheim Investigational Site, Bucheon, Korea, Republic of
Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life
- Conditions
- Parkinson Disease
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1703
- Registration Number
- NCT01100073
- Locations
- 🇷🇴
Boehringer Ingelheim Investigational Site 89, Focsani, Romania
🇷🇴Boehringer Ingelheim Investigational Site 102, Pascani, Romania
🇷🇴Boehringer Ingelheim Investigational Site 117, Teleorman, Romania
Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 329
- Registration Number
- NCT01097421
BI 671800 ED in Steroid-naive Asthmatic Patients
- Conditions
- Asthma
- Interventions
- Drug: BI 671800 Placebo
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 389
- Registration Number
- NCT01092143
- Locations
- 🇨🇦
1268.17.02003 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇺🇸1268.17.01034 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸1268.17.01027 Boehringer Ingelheim Investigational Site, Novi, Michigan, United States
Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids
- First Posted Date
- 2010-03-19
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 108
- Registration Number
- NCT01090024
- Locations
- 🇺🇸
1268.53.01013 Boehringer Ingelheim Investigational Site, Huntington Beach, California, United States
🇺🇸1268.53.01014 Boehringer Ingelheim Investigational Site, Mission Viejo, California, United States
🇺🇸1268.53.01001 Boehringer Ingelheim Investigational Site, North Dartmouth, Massachusetts, United States
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
- First Posted Date
- 2010-03-19
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 171
- Registration Number
- NCT01090011
- Locations
- 🇺🇸
1200.71.1001 Boehringer Ingelheim Investigational Site, New York, New York, United States
🇺🇸1200.71.1004 Boehringer Ingelheim Investigational Site, Aurora, Colorado, United States
🇳🇱1200.71.2002 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 241
- Registration Number
- NCT01087502
- Locations
- 🇦🇺
1218.64.61002 Boehringer Ingelheim Investigational Site, St Leonards, New South Wales, Australia
🇨🇦1218.64.20007 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada
🇨🇦1218.64.20008 Boehringer Ingelheim Investigational Site, Corunna, Ontario, Canada
LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: Investigator´s choice of chemotherapy
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1154
- Registration Number
- NCT01085136
- Locations
- 🇬🇧
Boehringer Ingelheim Investigational Site, Truro, Cornwall, United Kingdom